FTH Company Profile and Key Details

Average 10-day trading volume of 296.22 thousand shares is slightly above the 3-month average of 255.90 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $60.00 to $51.00. The high target offers 86.92% upside. The low target suggests 58.88% downside. The mean target is $56.25. This offers 75.23% upside. Faeth Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 04, 2026, missed forecasts by 7.58%. The prior quarter beat by 21101.61%. Over the last six quarters, Apple has recorded several small beats. These include -22.25% in March 30, 2026.

Faeth Therapeutics, Inc. has 25.78 million shares outstanding. The public float is 1.17 million shares, elevated short interest at 3.51% of float. This equals 890.31 thousand shares. The short ratio is 4.98 days. Institutional investors hold 26.37% of the float. Insiders own 1.45%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Faeth Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.68. This means the shares are trading above this model’s fair value.

Faeth Therapeutics, Inc. (NASDAQ:FTH) closed at $32.00 USD, losing -$0.10 (-0.31%) from the previous close of $32.10. The stock is currently mid-range between its 52-week high and low $7.45 and $37.90. With a market capitalization of about $824.92 million, Faeth Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~-0.31). Key stats such as the average daily volume over the past year has been around 199.67 thousand shares, trading with heavier-than-usual volume. Headquartered in Rockville, MD, Faeth Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Anand Parikh, the company employs approximately 29 people and listed since February 04, 2021. Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways.

Our AI price prediction model suggests that Faeth Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.34%, with price expected at $32.21 by September 03, 2026, within a range of $28.43 to $36.06 3-Month Outlook: Projected rise of 45.58%, reaching $46.73 by November 18, 2026, with a range of $46.44 to $47.07. 1-Year Outlook: Projected gain of 2654.39%, with price at $884.16 by August 20, 2027, within a range of $883.74 to $884.60.

Valuation shows Faeth Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.23. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $56.25, suggesting 75.23% upside. Our AI forecast model points to short-term strength (0.34% over two weeks), a medium-term rise (45.58% over three months), and a longer-term gain (2654.39% over one year), with expected trading ranges indicating moderate volatility.

Faeth Therapeutics, Inc. trades at a P/E ratio of -0.23, slightly below the S&P 500 average, with a price-to-sales ratio of -171.81 and a price-to-book ratio of 1.05 suggesting the stock is closer to book value. The P/FCF stands at -24.61, also below market averages.